01996nas a2200349   4500000000100000008004100001260001300042653001000055653001500065653003000080653001100110653002300121653002400144653002500168653000900193653001400202653001500216653001300231653000900244653001700253653002200270653002200292100001300314700001200327700001500339700001900354245016400373300001000537490000700547520107800554022001401632       1999                            d  c1999 Nov10aAdult10aBangladesh10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aLeprosy, Borderline10aLeprosy, Tuberculoid10aMale10aOfloxacin10aRecurrence10aRifampin10aSkin10aTime Factors10aTreatment Outcome10aTreatment Refusal1 aIshida Y1 aOzaki M1 aPicorini L1 aGuglielmelli E00aA recurrent case of BT leprosy with widely spread skin lesions showing a histopathology of indeterminate group after 4.5-years irregular treatment, Bangladesh.  a195-90 v683 a<p>A 29 year-old Bengali male case is presented in this paper which was a borderline tuberculoid leprosy (BT) at detection. His father contracted a lepromatous leprosy of G = 2 deformity. He took anti-leprosy drugs including MDT/MB regimen irregularly and had maculae widely-spread with anesthesia 16 months after being released from treatment (RFT). The histopathology of the maculae unexpectedly showed that of an indeterminate group of leprosy. The recurrent skin lesions were susceptive to a four-week regimen of Rifampicin and Ofloxacin. This case can not be defined as a relapsed case, because slit skin smears were always negative. It would be called a recurrent case after MDT/MB regimen. Though the reason recurrent skin lesions occur is unknown, it is reasonable to assume that the recurrent lesions are caused by dormant persisters which are originally drug sensitive. The recurrent skin lesions can not be classified because the clinical features can not be matched to their histology. Such recurrent cases might occur among the defaulters of MDT in future.</p>  a1342-3681